Previous 10 | Next 10 |
Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of several TCRs for multiple HLAs across multiple targets; INDs filed for two MAGE-A1 TCRs ...
WALTHAM, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced a poster present...
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced it has been name...
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that manag...
TCRs for an HLA-A*02:01 epitope of PRAME now in IND-enabling studies Multiplexing TCRs for MAGE-A1 and PRAME demonstrates synergistic cytotoxicity in vitro and in mouse xenograft models Company continues to discover TCRs for its ImmunoBank, enabling customized multiplexe...
TScan Therapeutics press release ( NASDAQ: TCRX ): Q3 GAAP EPS of -$0.67 beats by $0.05 . Revenue of $3.36M (+39.4% Y/Y) misses by $0.57M . Shares -5.66% PM. For further details see: TScan Therapeutics GAAP EPS of -$0.67 beats by $0.05, revenue of...
Four sites for hematologic malignancies program open and enrolling patients Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET to highlight clinical trial design Ended quarter with cash and cash equiv...
Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors Monday, November 14 th at 5:00 PM ET WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on...
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the ...
The following slide deck was published by TScan Therapeutics, Inc. in conjunction with this event. For further details see: Tscan Therapeutics (TCRX) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...